Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.

Autor: Fariña-Sarasqueta A; Department of Molecular Diagnostics, PAMM Laboratory of Pathology, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands., van Lijnschoten G, Rutten HJ, van den Brule AJ
Jazyk: angličtina
Zdroj: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2010 Nov; Vol. 66 (6), pp. 1167-71. Date of Electronic Publication: 2010 Jul 28.
DOI: 10.1007/s00280-010-1403-0
Abstrakt: Purpose: The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma.
Methods: DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping.
Results: None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival.
Conclusion: In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.
Databáze: MEDLINE
Externí odkaz: